MedTrace Logo

Study to Evaluate LPH-5 in Healthy Subjects

NCT06722820 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2024-12-09

No results posted yet for this study

Summary

This study will explore the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of LPH-5.

Conditions

  • Safety Issues
  • Tolerance

Interventions

DRUG

LPH-5

LPH-5

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Biotrial

    collaborator INDUSTRY

  • Lophora

    lead INDUSTRY

Principal Investigators

  • Sophie Hays, MD · Biotrial

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-04-30
Primary Completion
2025-11-30
Completion
2025-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06722820 on ClinicalTrials.gov